Medicine & Life Sciences
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
26%
Acute Myeloid Leukemia
95%
Allogeneic Cells
25%
Azacitidine
20%
B-Lymphocytes
10%
Blast Crisis
14%
blinatumomab
30%
Bone Marrow
11%
Clofarabine
14%
Cyclophosphamide
9%
Cytarabine
27%
Cytogenetics
27%
Dasatinib
36%
Decitabine
27%
Dexamethasone
8%
Drug Therapy
24%
fludarabine
10%
GATA2 Deficiency
11%
Gemtuzumab
7%
Hematologic Neoplasms
8%
Hematopoietic Stem Cell Transplantation
8%
Idarubicin
10%
Imatinib Mesylate
56%
INCB018424
9%
Inotuzumab Ozogamicin
41%
Leukemia
24%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
96%
Leukemia, Myeloid, Chronic Phase
45%
Leukemia, Myelomonocytic, Chronic
15%
Mutation
26%
Myelodysplastic Syndromes
59%
Neoplasms
12%
Philadelphia Chromosome
45%
Phosphotransferases
8%
ponatinib
29%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
100%
Primary Myelofibrosis
10%
Progression-Free Survival
12%
Protein-Tyrosine Kinases
73%
Recurrence
13%
Residual Neoplasm
11%
Safety
11%
Salvage Therapy
8%
Stem Cell Transplantation
24%
Survival
42%
Survival Rate
11%
Therapeutics
36%
Transplants
10%
venetoclax
41%
Vincristine
11%